Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying ...

Within a large group of more than 700 patients treated with CAR T cell therapy, researchers found no evidence that the therapy itself caused any type of secondary cancer in the modified T cells, ...

Within a large group of more than 700 patients treated with CAR T cell therapy, researchers found no evidence that the ...

This valuable study presents a mouse gastruloid model that can be used to generate hematopoietic progenitors as well as leukemic cells. However, in its current form, the manuscript is inadequate ...

Jan. 14, 2025 — A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients. The ...

Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...

The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.

The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.

Boston – Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who ...

If acute forms of leukemia are involved, the onset may be sudden. If chronic forms are involved, they may develop slowly and be harder to recognize. The symptoms are largely due to the onset of anemia ...

Qartemi is a personalised Chimeric Antigen Receptor or CAR-T cell for adult patients with relapsed or refractory ... 1,20,000 new cases and over 70,000 deaths annually from leukemia, lymphoma, and ...